|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Biomet U.K. Ltd. |
|---|---|
| Information provided by (Responsible Party): | Biomet, Inc. ( Biomet U.K. Ltd. ) |
| ClinicalTrials.gov Identifier: | NCT00859976 |
Purpose
The randomised controlled trial will be carried out on patients that require a total hip replacement (THR) to reduce pain and restore their function. One way of fixing the hip joint to the bone is by coating the implant to encourage the body to grow bone onto the replacement hip. This study is aiming to find out whether the new (Bonemaster) coating allows increased bony growth onto the cup when compared to the usual (plasma-sprayed) coating. This may reduce the incidence of early failures due to poor bony attachment, which is a well known complication for early failure of total hip replacements.
The study will compare two different types of coating (BoneMaster and Plasma-sprayed) on the cup of the replacement hip. Density of the bone immediately surrounding the cup will be observed to see if there are differences between the two groups. The density of bone will be measured using standard x−ray assessment and in a smaller sample of 14 patients, using a special scan called Dual Energy X−ray Absorptiometry (DEXA Scan). Functional comparisons will be assessed through clinical scores.
| Condition | Intervention |
|---|---|
|
Arthropathy of Hip |
Device: BoneMaster coated acetabular shell. Device: Plasma Coated Acetabular Shell |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Prospective Randomised Control Trial to Compare the Effect Upon Bone Density and Clinical Outcomes When Using BoneMaster HA Coated Acetabular Cups Compared With Plasma Sprayed HA Coated Cups in Patients With Total Hip Replacements |
| Estimated Enrollment: | 210 |
| Study Start Date: | March 2009 |
| Estimated Study Completion Date: | August 2024 |
| Estimated Primary Completion Date: | August 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Plasma-sprayed shell
Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
|
Device: Plasma Coated Acetabular Shell
Plasma HA coated Exceed Acetabular Shell
Other Name: Plasma Hydroxyapatite coated Exceed Acetabular Shell
|
|
Experimental: BoneMaster coated shell
Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
|
Device: BoneMaster coated acetabular shell.
Bonemaster coated Exceed Acetabular Shell
Other Name: Bonemaster coated Exceed Acetabular Shell
|
The patients will be identified by the orthopaedic surgeon in the orthopaedic clinic and deemed suitable for the study if all inclusion and exclusion criteria are met. 210 patients will be recruited to the study and each patient will be randomised into either of the groups allowing 105 patients into each group. Patients will be followed up at 6 months, 1 year and 2 years after the surgery. All patients will have radiographic assessments at these follow-up intervals, as well as Harris Hip, Oxford Hip and Womac scores. This will allow comparison of the two groups.
The BoneMaster coating has been extensively tested in cell and animal studies and has been evaluated in one previous clinical study and showed favorable results. Further investigation is required to ensure the new coating may enhance bony growth allowing better fixation of the hips in the early period after the operation and also over a longer period of time. The growth needs to be measured using a more sensitive scan than radiographic assessment alone, called DEXA which was also used in the previous study.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Contacts and Locations| Contact: Helmut Zahn, FRCS | +441233 616085 | HELMUT.ZAHN@ekht.nhs.uk |
| Belgium | |
| CHU Saint Pierre | Recruiting |
| Bruxelles, Belgium | |
| Contact: Philippe DELINCE, Pr | |
| Principal Investigator: Philippe DELINCE, Pr | |
| Sub-Investigator: Dior GHAFIL, Dr | |
| United Kingdom | |
| William Harvey Hospital | Recruiting |
| Ashford, Kent, United Kingdom, TN24 0LZ | |
| Principal Investigator: Helmut Zahn, FRCS | |
| Principal Investigator: | Helmut ZAHN | William Harvey Hospital |
More Information
| Responsible Party: | Biomet, Inc. ( Biomet U.K. Ltd. ) |
| ClinicalTrials.gov Identifier: | NCT00859976 History of Changes |
| Other Study ID Numbers: | EU27, UK REC Ref: 08/H0724/24 |
| Study First Received: | March 6, 2009 |
| Last Updated: | December 13, 2011 |
| Health Authority: | United Kingdom: Research Ethics Committee |
|
BoneMaster Total Hip Replacement Bone Density Patients suitable for Total Hip Replacement |
|
Joint Diseases Musculoskeletal Diseases |